: As COVID vaccine and Paxlovid sales decline, analysts want to know what’s next for Pfizer

Bank of America analysts downgraded the stock to neutral from buy.

Previous post Economic Report: U.S. adds robust 223,000 jobs in December, but wage growth slows in sign of ebbing inflation pressures
Next post : On anniversary of the Capitol attack, companies face new pressures to disclose political spending